SpringerLink
Log in

Wer zahlt für komplementäre und alternative Medizin?

Who pays for complementary and alternative medicine?

  • Kosten von Krebserkrankungen
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Alsawaf MA, Jatoi A (2007) Shop** for nutrition-based complementary and alternative medicine on the Internet: how much money might cancer patients be spending online? J Cancer Educ 22:174–176. https://doi.org/10.1007/BF03174332

    Article  PubMed  Google Scholar 

  2. Ambrosone CB, Zirpoli GR, Hutson AD et al (2020) Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). J Clin Oncol 38:804–814. https://doi.org/10.1200/JCO.19.01203

    Article  CAS  PubMed  Google Scholar 

  3. Bhoo-Pathy N, Subramaniam S, Khalil S et al (2021) Out-of-pocket costs of complementary medicine following cancer and the financial impact in a setting with universal health coverage: findings from a prospective cohort study. JCO Oncol Pract 17:e1592–e1602. https://doi.org/10.1200/OP.20.01052

    Article  PubMed  Google Scholar 

  4. Bundesverband der Pharmazeutischen Industrie e. V. (BPI) (2022) OTC-Daten 2022 – Selbstmedikation – die zweite tragende Säule der Arzneimittelversorgung des deutschen Gesundheitssystems – Zahlen, Daten, Fakten

    Google Scholar 

  5. Chebli P, Lemus J, Avila C et al (2020) Multilevel determinants of financial toxicity in breast cancer care: perspectives of healthcare professionals and Latina survivors. Support Care Cancer 28:3179–3188. https://doi.org/10.1007/s00520-019-05119-y

    Article  PubMed  Google Scholar 

  6. Coulter ID, Herman PM, Nataraj S (2013) Economic analysis of complementary, alternative, and integrative medicine: considerations raised by an expert panel. BMC Complement Altern Med 13:191. https://doi.org/10.1186/1472-6882-13-191

    Article  PubMed  PubMed Central  Google Scholar 

  7. Eschiti VS (2007) Lesson from comparison of CAM use by women with female-specific cancers to others: it’s time to focus on interaction risks with CAM therapies. Integr Cancer Ther 6:313–344. https://doi.org/10.1177/1534735407309257

    Article  PubMed  Google Scholar 

  8. Gunn AH, Sorenson C, Greenup RA (2021) Navigating the high costs of cancer care: opportunities for patient engagement. Future Oncol 17:3729–3742. https://doi.org/10.2217/fon-2021-0341

    Article  CAS  PubMed  Google Scholar 

  9. Han S, Jang B‑H, Suh HS, Hwang D‑S (2019) Complementary medicine use and costs in patients with breast cancer who experienced treatment-related side effects: a cross-sectional survey in korea. Complement Ther Med 44:210–217. https://doi.org/10.1016/j.ctim.2019.04.013

    Article  PubMed  Google Scholar 

  10. Herman PM, Craig BM, Caspi O (2005) Is complementary and alternative medicine (CAM) cost-effective? a systematic review. BMC Complement Altern Med 5:11. https://doi.org/10.1186/1472-6882-5-11

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hershman DL, Unger JM, Crew KD et al (2018) Two-year trends of taxane-induced neuropathy in women enrolled in a randomized trial of acetyl-L-carnitine (SWOG S0715). J Natl Cancer Inst 110:669–676. https://doi.org/10.1093/jnci/djx259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hollin IL, González JM, Buelt L et al (2020) Do patient preferences align with value frameworks? A discrete-choice experiment of patients with breast cancer. MDM Policy Pract 5:2381468320928012. https://doi.org/10.1177/2381468320928012

    Article  PubMed  PubMed Central  Google Scholar 

  13. Horneber M, Bueschel G, Dennert G et al (2012) How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther 11:187–203. https://doi.org/10.1177/1534735411423920

    Article  PubMed  Google Scholar 

  14. Huebner J, Micke O, Muecke R et al (2014) User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res 34:943–948

    PubMed  Google Scholar 

  15. Huebner J, Prott FJ, Muecke R et al (2017) Economic evaluation of complementary and alternative medicine in oncology: is there a difference compared to conventional medicine? Med Princ Pract 26:41–49. https://doi.org/10.1159/000450645

    Article  PubMed  Google Scholar 

  16. Husereau D, Drummond M, Petrou S et al (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health 16:e1–5. https://doi.org/10.1016/j.jval.2013.02.010

    Article  PubMed  Google Scholar 

  17. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Neue Arzneimittel: Zulassung, Nutzenbewertung, Erstattung. https://www.iqwig.de/presse/im-fokus/neue-arzneimittel-zulassung-nutzenbewertung-erstattung/. Zugegriffen: 16. Dez. 2022

  18. Johnson SB, Park HS, Gross CP, Yu JB (2018) Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx145

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jung AY, Cai X, Thoene K et al (2019) Antioxidant supplementation and breast cancer prognosis in postmenopausal women undergoing chemotherapy and radiation therapy. Am J Clin Nutr 109:69–78. https://doi.org/10.1093/ajcn/nqy223

    Article  PubMed  Google Scholar 

  20. Kennedy DA, Hart J, Seely D (2009) Cost effectiveness of natural health products: a systematic review of randomized clinical trials. Evid Based Complement Alternat Med 6:297–304. https://doi.org/10.1093/ecam/nem167

    Article  PubMed  Google Scholar 

  21. Kienle GS, Albonico H‑U, Fischer L et al (2011) Complementary therapy systems and their integrative evaluation. Explore (NY) 7:175–187. https://doi.org/10.1016/j.explore.2011.02.001

    Article  PubMed  Google Scholar 

  22. Kienle GS, Kiene H, Albonico HU (2006) Anthroposophic medicine: health technology assessment report—short version. Forsch Komplementmed 13(2):7–18. https://doi.org/10.1159/000093481

    Article  PubMed  Google Scholar 

  23. Kim SY, Kim KS, Park JH et al (2013) Factors associated with discontinuation of complementary and alternative medicine among Korean cancer patients. Asian Pac J Cancer Prev 14:225–230. https://doi.org/10.7314/apjcp.2013.14.1.225

    Article  PubMed  Google Scholar 

  24. Kligler B, Homel P, Harrison LB et al (2011) Cost savings in inpatient oncology through an integrative medicine approach. Am J Manag Care 17:779–784

    PubMed  Google Scholar 

  25. Längler A, Boeker R, Kameda G et al (2013) Attitudes and beliefs of paediatric oncologists regarding complementary and alternative therapies. Complement Ther Med 21(1):S10–19. https://doi.org/10.1016/j.ctim.2012.02.006

    Article  PubMed  Google Scholar 

  26. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2020) Komplementärmedizin in der Behandlung von onkologischen PatientInnen. https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/ (Langversion 1.1, 2021, AWMF Registernummer: 032/055OL)- Zugegriffen: 06.03.2023>

  27. Longo CJ, Fitch MI, Loree JM et al (2021) Patient and family financial burden associated with cancer treatment in Canada: a national study. Support Care Cancer 29:3377–3386. https://doi.org/10.1007/s00520-020-05907-x

    Article  PubMed  PubMed Central  Google Scholar 

  28. Luo Z, Wang L, Sikorskii A, Wyatt G (2019) Healthcare service utilization and work-related productivity in reflexology intervention for advanced breast cancer women. Support Care Cancer 27:2837–2847. https://doi.org/10.1007/s00520-018-4592-4

    Article  PubMed  Google Scholar 

  29. Miller M, Boyer MJ, Butow PN et al (1998) The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost. Support Care Cancer 6:337–347. https://doi.org/10.1007/s005200050175

    Article  CAS  PubMed  Google Scholar 

  30. Molassiotis A, Dawkins B, Longo R et al (2021) Economic evaluation alongside a randomised controlled trial to assess the effectiveness and cost-effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Acupunct Med 39:41–52. https://doi.org/10.1177/0964528420920285

    Article  PubMed  Google Scholar 

  31. Molassiotis A, Fernández-Ortega P, Pud D et al (2005) Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 16:655–663. https://doi.org/10.1093/annonc/mdi110

    Article  CAS  PubMed  Google Scholar 

  32. Molassiotis A, Russell W, Hughes J et al (2013) The effectiveness and cost-effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: assessment of nausea in chemotherapy research (ANChoR), a randomised controlled trial. Health Technol Assess 17:1–114. https://doi.org/10.3310/hta17260

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Rivera AS (2022) Complementary medicine as a risk factor for catastrophic expenditures in people with cancer. Lancet Glob Health 10:e313–e314. https://doi.org/10.1016/S2214-109X(22)00034-1

    Article  CAS  PubMed  Google Scholar 

  34. Spinks J, Hollingsworth B (2009) Are the economics of complementary and alternative medicine different to conventional medicine? Expert Rev Pharmacoeconomics Outcomes Res 9:1–4. https://doi.org/10.1586/14737167.9.1.1

    Article  Google Scholar 

  35. Standish LJ, Dowd F, Sweet E et al (2017) Breast cancer integrative oncology care and its costs. Integr Cancer Ther 16:85–95. https://doi.org/10.1177/1534735416649034

    Article  PubMed  Google Scholar 

  36. Statista (2022) Nahrungsergänzungsmittel: Umsatz nach Vertriebslinien. https://de.statista.com/statistik/daten/studie/1308546/umfrage/umsatz-mit-nahrungsergaenzungsmitteln-nach-vertriebslinien/. Zugegriffen: 22. Dez. 2022

  37. Statista OTC Pharma – Deutschland | Statista Marktprognose. https://de.statista.com/outlook/cmo/otc-pharma/deutschland. Zugegriffen: 22. Dez. 2022

  38. Thronicke A, Reinhold T, von Trott P et al (2020) Cost-effectiveness of real-world administration of chemotherapy and add-on viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. PLoS ONE 15:e236426. https://doi.org/10.1371/journal.pone.0236426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wieseler B, McGauran N, Kaiser T (2019) New drugs: where did we go wrong and what can we do better? BMJ 366:l4340. https://doi.org/10.1136/bmj.l4340

    Article  PubMed  Google Scholar 

  40. Witt CM (2011) Health economic studies on complementary and integrative medicine. Forsch Komplementmed 18:6–9. https://doi.org/10.1159/000324615

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Deutschland

    Jutta Hübner & Christian Keinki

  2. RNS Praxisgemeinschaft, Wiesbaden, Deutschland

    Franz-Josef Prott

  3. Klinik für Hals-Nasen-Ohren-Heilkunde, Südharzklinikum Nordhausen, Nordhausen, Deutschland

    Jens Büntzel

  4. Klinik für Strahlentherapie, Franziskus Hospital, Bielefeld, Deutschland

    Oliver Micke

Authors
  1. Jutta Hübner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franz-Josef Prott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jens Büntzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oliver Micke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Keinki
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Arbeitsgemeinschaft Prävention und Integrative Onkologie

Corresponding author

Correspondence to Jutta Hübner.

Ethics declarations

Interessenkonflikt

J. Hübner, F.-J. Prott, J. Büntzel, O. Micke, C. Keinki und die Arbeitsgemeinschaft Prävention und Integrative Onkologie geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hübner, J., Prott, FJ., Büntzel, J. et al. Wer zahlt für komplementäre und alternative Medizin?. Forum 38, 141–146 (2023). https://doi.org/10.1007/s12312-023-01187-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-023-01187-8

Search

Navigation